Kenota (formerly ExVivo Labs)
Kenota, headquartered in Kitchener, ON, Canada, specializes in healthcare diagnostics, providing innovative in-clinic allergy testing systems that enable rapid and accurate allergy testing.
Company History
Kenota, initially known as ExVivo Labs, was founded with a focus on revolutionizing allergy diagnostics within healthcare. Their concept for an in-clinic allergy testing system was developed in 2018. In 2019, Kenota established a scalable 33,000 square-foot manufacturing facility in the Waterloo Region, Canada. The company conducted a successful allergy clinic pilot study and created pilot systems in 2020. In 2020, they also raised $11 million in Series A funding. Kenota submitted their technology to the FDA in 2023. The company is headquartered in Kitchener, ON, Canada.
Allergy Testing Technology
Kenota offers accurate and rapid testing for allergies directly in an allergist's office. Their technology provides lab-quality IgE testing capabilities, making it easier for allergists to uncover sensitizations with a few drops of blood. This system enables allergists to provide comprehensive care in a single visit, eliminating the need for lab referrals. The testing system is compact, streamlined, and user-friendly for allergists and their staff.
Founders and Y-Combinator S16 Batch
Kenota, formerly ExVivo Labs, participated in the Y Combinator S16 batch. This involvement helped shape the company's direction and facilitated its growth in the healthcare diagnostics industry. The support and resources from Y Combinator played a significant role in Kenota's development and success.
Manufacturing Facility
In 2019, Kenota established a 33,000 square-foot manufacturing facility in the Waterloo Region, Canada. This scalable facility is crucial for the production of their rapid allergy testing systems. The manufacturing capabilities ensure that Kenota can meet the growing demand for their innovative diagnostic solutions.
Market Presence and Funding
Kenota operates in the healthcare diagnostics industry, specifically focusing on allergy testing. The company has a presence in Canada and America, with partly remote operations. In 2020, Kenota successfully raised $11 million in Series A funding. This financial support has been instrumental in advancing their technology and expanding their market presence.